2022 Medium-Term Management Plan: Investing in Growth Markets and New Technologies through “Challenge and Co-Creation”
First written in FY2020. 8 of 18 entries say "Restated". Latest entry: FY2026.
Nof moved to the "Worse" side of this theme in 2026, the same year as the typical company in this theme.
The whole theme swung hardest in 2022: 2 of 10 companies on the "Worse" side.
5 other companies' latest entry also says "Reframed".
- FY2026ReframedAnnual report
「Under the 2028 Medium-Term Management Plan, the Company has adopted “Transformation and Creation” as its basic policy and will address the following issues: “expansion of business domains by capturing market opportunities,” “creation of new technologies and businesses,” “productivity improvement and operational efficiency,” “pursuit of safety and security,” and “promotion of CSR.”」
The Company transitioned from the 2022 Medium-Term Management Plan through the 2025 Medium-Term Management Plan to the 2028 Medium-Term Management Plan. With “Transformation and Creation” as its basic policy, it reorganized its priorities into 5 issues: expansion of business domains, new technologies and businesses, productivity, safety and security, and CSR. - FY2026-H1AdvancedAnnual report
「This fiscal year, we will also implement the "Industry-Academia Contract Research-Type Open Innovation Program 2025," which solicits the development of next-generation materials and technologies in the electronics field, where growth is expected, and contribute to the realization of a sustainable society and the future chemical industry while accelerating the development of new products and technologies.」
Regarding new product and new technology development under the 2025 Medium-Term Management Plan, the Company conducted a 2025 industry-academia commissioned research-based open innovation program targeting the electronics sector. - FY2025AdvancedAnnual report
「The expansion of the cosmetics ODM line in the Functional Chemicals business at the Aichi Plant began operations as scheduled. In the Pharmaceutical, Medical and Health business, the new manufacturing facilities for DDS pharmaceutical formulation ingredients, whose construction was undertaken in anticipation of future growth in the market for biopharmaceuticals such as nucleic acid drugs, have also entered the preparation stage for operations to begin as scheduled.」
As a business expansion initiative under the 2025 Mid-Term Management Plan, we reached the milestone of beginning operations at the cosmetics ODM line, while the DDS pharmaceutical formulation ingredients facilities progressed to the preparation stage for operations. - FY2025-H1AdvancedAnnual report
「Beginning this fiscal year, we also established the NOF-AIST Smart Green Chemicals Collaborative Research Laboratory at the National Institute of Advanced Industrial Science and Technology (AIST), and will contribute to the realization of a sustainable society and the future chemical industry while accelerating the development of new products and technologies.」
With respect to new product and technology development under the 2025 Mid-Term Management Plan, this indicates concrete progress toward establishing a collaborative research laboratory with AIST. - FY2024AdvancedAnnual report
「To accelerate "expanding our business by responding to market changes," we will pursue active strategic investment in the 3 target fields. In the Functional Chemicals business, we will proceed with expanding the cosmetics ODM line at the Aichi Plant. In the Pharmaceutical, Medical and Health business, anticipating growth in the future market for biopharmaceuticals such as nucleic acid drugs, we will proceed with constructing new manufacturing facilities for DDS pharmaceutical formulation ingredients at the Aichi Plant.」
Under the 2025 Mid-Term Management Plan, we are proceeding with the expansion of the cosmetics ODM line and the construction of new facilities for DDS pharmaceutical formulation ingredients at the Aichi Plant. We have expanded the scope of open innovation to the medical and medical device fields and other areas, and continue to pursue DX, MI, and smart-factory initiatives. - FY2024-Q2AdvancedAnnual report
「In addition to the initiatives undertaken last fiscal year to co-create businesses through open innovation in the electronics and health food fields, this fiscal year we are also implementing them in the medical and medical device fields to accelerate the development of new products and technologies.」
With respect to new product and technology development under the 2025 Mid-Term Management Plan, we expanded the scope of business co-creation through open innovation to the medical and medical device fields. - FY2024-Q1ReframedAnnual report
「Under the three-year 2025 Mid-Term Management Plan, whose first year is the current fiscal year, we adopted "Execution and Advancement" as the basic policy and addressed the following issues: expanding our business by responding to market changes, accelerating the development of new products and technologies, improving productivity, pursuing safety and security, and promoting CSR,」
Following the final year of the 2022 Mid-Term Management Plan, we transitioned to the 2025 Mid-Term Management Plan. "Expanding our business in growth markets" was changed to "expanding our business by responding to market changes," and the issues were reorganized. - FY2023-Q3RestatedAnnual report
「Under the three-year 2022 Mid-Term Management Plan, whose final year is fiscal 2022, the Group adopted "Challenge and Co-creation" as its basic policy and addressed the following issues: expanding our business in growth markets, accelerating the development of new products and technologies, strengthening collaboration inside and outside the Group, improving productivity, and promoting CSR activities,」
In the final year of the 2022 Mid-Term Management Plan, we continue to pursue the 5 issues of growth markets, new products and technologies, collaboration, productivity, and CSR. - FY2023-Q1RestatedAnnual report
「Under the three-year 2022 Mid-Term Management Plan, whose final year is fiscal 2022, the Group adopted "Challenge and Co-creation" as its basic policy and addressed the following issues: expanding our business in growth markets, accelerating the development of new products and technologies, strengthening collaboration inside and outside the Group, improving productivity, and promoting CSR activities, while working to develop new markets, expand sales, and reduce production costs.」
In the final year of the 2022 Mid-Term Management Plan, we continue to pursue the basic policy and the 5 issues. No new milestones involving specific facility expansions or the establishment of an R&D structure were reported in the first quarter. - FY2022AdvancedAnnual report
「To further expand our business in growth markets, we expanded manufacturing facilities for ethylene oxide (EO) derivatives and DDS pharmaceutical formulation ingredients at the Kawasaki Plant to strengthen the supply capacity for products of the Functional Chemicals and Life Science businesses. To accelerate the development of new products and technologies, we promoted open innovation activities through industry-academia collaboration involving biochemicals and thermal control materials, with the aim of achieving harmony with society and the natural environment.」
To expand growth markets under the 2022 Mid-Term Management Plan, we expanded manufacturing facilities for EO derivatives and DDS pharmaceutical formulation ingredients at the Kawasaki Plant. For new product and technology development, we promoted open innovation in biochemicals and thermal control materials. - FY2022-Q3RestatedAnnual report
「Under the three-year 2022 Medium-Term Management Plan, which began in fiscal 2020, the Group adopted “Challenge and Co-creation” as its basic policy and addressed the priorities of expanding its business in growth markets, accelerating the development of new products and technologies, strengthening collaboration inside and outside the Group, improving productivity, and promoting CSR activities. At the same time, it worked to develop new markets and expand sales of high-performance, high-value-added products, reduce production costs, and build on its management efforts toward sustainable growth.」
We continue to pursue the basic policy and the 5 issues of the 2022 Mid-Term Management Plan. - FY2022-Q2AdvancedAnnual report
「To expand our business in growth markets, we proceeded with the expansion of manufacturing facilities for DDS pharmaceutical formulation ingredients at the Kawasaki Plant to strengthen the production structure of the Life Science business. To accelerate the development of new products and technologies, we promoted active participation in open innovation through industry-government-academia collaboration and worked to establish a company-wide R&D structure to improve R&D efficiency through the introduction of materials informatics (MI) using data science.」
Under the 2022 Mid-Term Management Plan, we are proceeding with the expansion of DDS manufacturing facilities, participation in open innovation, the introduction of MI, and the establishment of a company-wide R&D structure in connection with the expansion of growth markets and the development of new products and technologies. - FY2022-Q1RestatedAnnual report
「Under the three-year 2022 Mid-Term Management Plan, whose first year was fiscal 2020, the Group adopted "Challenge and Co-creation" as its basic policy and addressed the following issues: expanding our business in growth markets, accelerating the development of new products and technologies, strengthening collaboration inside and outside the Group, improving productivity, and promoting CSR activities,」
In the first year of the 2022 Mid-Term Management Plan, we continue to pursue the basic policy and the 5 issues. - FY2021RestatedAnnual report
「This fiscal year, the Group will continue to implement measures under the basic policy of “Challenge and Co-creation” in the three-year 2022 Medium-Term Management Plan, which began in fiscal 2020, addressing the priorities of expanding its business in growth markets, accelerating the development of new products and technologies, strengthening collaboration inside and outside the Group, improving productivity, and promoting CSR activities.」
In the first year of the 2022 Mid-Term Management Plan, we continue to pursue the basic policy and the 5 issues. - FY2021-Q3RestatedAnnual report
「Under the three-year 2022 Medium-Term Management Plan, which begins in the current fiscal year, the Group has adopted “Challenge and Co-creation” as its basic policy and is addressing the priorities of expanding its business in growth markets, accelerating the development of new products and technologies, strengthening collaboration inside and outside the Group, improving productivity, and promoting CSR activities. At the same time, it has worked to develop new markets and expand sales of high-performance, high-value-added products, reduce production costs, and build on its management efforts toward sustainable growth.」
In the first year of the 2022 Mid-Term Management Plan, we continue to pursue the basic policy, the 5 issues, expanded sales of high-performance, high-value-added products, and reductions in production costs. - FY2021-Q2RestatedAnnual report
「Under the three-year 2022 Medium-Term Management Plan, which begins in the current fiscal year, the Group has adopted “Challenge and Co-creation” as its basic policy and is addressing the priorities of expanding its business in growth markets, accelerating the development of new products and technologies, strengthening collaboration inside and outside the Group, improving productivity, and promoting CSR activities」
In the first year of the 2022 Mid-Term Management Plan, we continue to pursue the basic policy and the 5 issues. - FY2021-Q1RestatedAnnual report
「Under the three-year 2022 Medium-Term Management Plan, which begins in the current fiscal year, the Group has adopted “Challenge and Co-creation” as its basic policy and is addressing the priorities of expanding its business in growth markets, accelerating the development of new products and technologies, strengthening collaboration inside and outside the Group, improving productivity, and promoting CSR activities」
In the first year of the 2022 Mid-Term Management Plan, we continue to pursue the basic policy of "Challenge and Co-creation" and the 5 issues. - FY2020First statedAnnual report
「Under the three-year 2022 Mid-Term Management Plan, whose first year is the current fiscal year, we identified the 3 target fields as Life and Healthcare, Electronics and Information, and Environment and Energy. The basic policy of the 2022 Mid-Term Management Plan is "Challenge and Co-creation," and we are addressing the following issues: expanding our business in growth markets, accelerating the development of new products and technologies, strengthening collaboration inside and outside the Group, improving productivity, and promoting CSR activities.」
A three-year plan following the 2019 Mid-Term Management Plan began in fiscal 2020, with 5 issues established under the basic policy.